McCallum R W, Ricci D A, Rakatansky H, Behar J, Rhodes J B, Salen G, Deren J, Ippoliti A, Olsen H W, Falchuk K
Gastroenterology Section, Yale University School of Medicine, New Haven, Connecticut 06510.
Diabetes Care. 1983 Sep-Oct;6(5):463-7. doi: 10.2337/diacare.6.5.463.
Metoclopramide tablets were compared with placebo in the treatment of gastrointestinal symptoms in 40 patients with diabetic gastroparesis. Results of a 3-wk double-blind study indicate that metoclopramide at a dosage of one 10-mg tablet four times daily reduced nausea, vomiting, fullness, and early satiety and improved meal tolerance better than placebo. Statistically significant differences were noted for nausea and postprandial fullness. Mean gastric emptying assessed by radionuclide scintigraphy was significantly improved in the metoclopramide-treated group when compared with their baseline result. Metoclopramide is an effective agent for improving the upper gastrointestinal motor function in diabetic patients with gastroparesis.
将胃复安片与安慰剂进行对比，用于治疗40例糖尿病性胃轻瘫患者的胃肠道症状。一项为期3周的双盲研究结果表明，每日4次、每次服用1片10毫克的胃复安，在减轻恶心、呕吐、饱腹感和早饱感方面比安慰剂更有效，且能更好地改善进餐耐受性。恶心和餐后饱腹感方面存在统计学上的显著差异。与基线结果相比，经放射性核素闪烁扫描评估，胃复安治疗组的平均胃排空有显著改善。胃复安是改善糖尿病性胃轻瘫患者上消化道运动功能的有效药物。
